AstraZeneca PLC Class Action Lawsuit - AZN

The filed complaint alleges that AstraZeneca PLC made materially false and/or misleading statements and/or failed to disclose that: AstraZeneca PLC faces a securities investigation after shares fell more than 8.3% in early trading on July 9, 2026. Wainua, a gene-silencing drug for transthyretin-mediated amyloid cardiomyopathy, had been positioned as a key value driver toward AstraZeneca's stated "$80 billion 2030 ambition." The Company referred to the trial as the “largest trial in this population” with the “potential to address key questions” unanswered in the community. On July 9, 2026, AstraZeneca reported that the trail had failed, noting that “adding Wainua did not provide a statistically significant benefit on the composite outcome of CV mortality and recurrent CV events.”

In order to be eligible to join the AZN class action lawsuit, you must have incurred a loss on shares of AstraZeneca PLC purchased during the class period listed above.